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Abstract
Background: Different methods to prevent contrast-associated acute kidney injury (CA-AKI) have been proposed in
recent years. We performed a mixed treatment comparison to evaluate and rank suggested interventions.
Methods: A comprehensive Systematic review and a Bayesian network meta-analysis of randomised controlled
trials was completed. Results were tabulated and graphically represented using a network diagram; forest plots and
league tables were shown to rank treatments by the surface under the cumulative ranking curve (SUCRA). A stacked
bar chart rankogram was generated. We performed main analysis with 200 RCTs and three analyses according to
contrast media and high or normal baseline renal profile that includes 173, 112 & 60 RCTs respectively.
Results: We have included 200 trials with 42,273 patients and 44 interventions. The primary outcome was CI-AKI,
defined as ≥25% relative increase or≥ 0.5 mg/dl increase from baseline creatinine one to 5 days post contrast
exposure. The top ranked interventions through different analyses were Allopurinol, Prostaglandin E1 (PGE1) & Oxygen
(0.9647, 0.7809 & 0.7527 in the main analysis). Comparatively, reference treatment intravenous hydration was ranked
lower but better than Placebo (0.3124 VS 0.2694 in the main analysis).
Conclusion: Multiple CA-AKI preventive interventions have been tested in RCTs. This network evaluates data for all the
explored options. The results suggest that some options (particularly allopurinol, PGE1 & Oxygen) deserve further
evaluation in a larger well-designed RCTs.
Keywords: Contrast induced acute kidney injury, Contrast nephropathy, Prevention methods, Contrast associated
acute kidney injury
Background
Rationale
Contrast Associated acute kidney injury (CA-AKI) also
known as Contrast-induced acute kidney injury (CI-AKI)
previously known as contrast induced nephropathy
(CIN) is the third leading cause of hospital-acquired
acute renal injury, accounting for 12% of cases [1]. It is
defined as an abrupt deterioration in renal function
following exposure to contrast media (CM) in the ab-
sence of other aetiological factors [2]. The absolute and
relative values used to define CI-AKI vary, but are most
commonly quoted as a relative increase of > 25% or an
absolute increase of 0.5 mg/dL and ≥ 0.3 mg from base-
line serum creatinine measurement within 1–3 (4–5 days
less frequently used) of contrast exposure [3–7]. In
CI-AKI, the serum creatinine level begins to rise within
24 h of contrast exposure, peaking after 72 h, and
usually returning to baseline within 1–3 weeks [6].
The proposed pathophysiology of CI-AKI is acute tubu-
lar necrosis. The underlying mechanisms are thought to
be vasoconstriction, leading to cellular hypoxia, or direct
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toxicity of contrast media to renal tubular cells [8, 9].
Multiple therapies have been postulated to prevent
CI-AKI act by affecting these mechanisms or their meta-
bolic mediators.
There is ongoing discussion about the impact of new
contrast media on the size of the problem and the out-
comes of prevention methods or even the existence of
the problem, on the other side these conclusions were
challenged as coming only from retrospective studies
that does not take in account patients factors or indica-
tions for using contrast media in deferent cases with def-
erent baseline renal profile [10, 11].
In recent years, there have been many systematic re-
views and meta-analyses for direct pair-wise compari-
sons of individual interventions suggested for CI-AKI
prevention. With so many options explored, it is difficult
to determine the treatment options most likely to show
benefit in large-scale trials. Unlike conventional
meta-analysis, Network facilitates simultaneous compari-
son of indirect relationships between multiple interven-
tions. The network can establish an estimate of
comparative efficacy between two or more treatments
compared to the same control intervention [12–14]. We
undertook a network-meta-analysis of preventive strat-
egies for CA-AKI to determine the treatment most likely
to be beneficial based upon currently available evidence.
Methods
We conducted a systematic review and network
meta-analysis in accordance with the PRISMA extension
for Network Meta-Analyses [15].
Protocol and registration
No registered protocol.
Eligibility criteria
We consider all randomized controlled trials in which
patients underwent a contrast-enhanced procedure with
CI-AKI as a primary or secondary outcome. We evaluate
studies in which a prevention method was compared to
placebo, control or other intervention. Excluded from
the analysis were other research designs, including
non-randomised control trials; clinical trials; trials com-
paring different doses of the same intervention and trials
using re-randomization of the same sample (Crossover
design). For this review, we defined CI-AKI as an in-
crease of more than or equal to 0.5 mg/dl and/or 25%
increase in baseline serum Creatinine one to 5 days post
contrast exposure [3].
Information sources
We searched for English-language trials in PubMed,
Embase and Cochrane Central Register of Controlled
Trials without any date restrictions. The final search was
undertaken on 25th April 2017.
Search strategy and study selection
Two authors (Ahmed, Walsh) searched Electronic data-
bases using Mesh terms “contrast nephropathy”, “con-
trast nephropathy prophylaxis”, “contrast nephropathy
prevention”, with the Boolean operator “OR” as appro-
priate. Titles and abstracts of identified studies were
assessed first, with full texts reviewed thereafter. The
study was included if the methodology fulfilled inclusion
criterion.
Data collection
Data were recorded concerning sample size, adverse
events, procedures performed, study inclusion and ex-
clusion criteria, intervention type and dose, contrast
media volume, CI-AKI definition, and contrast medium
type and osmolality.
The geometry of the network
A network diagram was created using NetMetaXL tool to
graphically represent the size of the trial and the number
of pairwise comparisons between interventions. The size
of each intervention node is proportional to a number of
patients included in the trial, while the thickness of inter-
connecting lines is proportional to the number of pairwise
comparisons between any two interventions.
Risk of bias
The Cochrane tool for risk of bias assessment (RevMan
5.3) was used to assess bias within individual studies. A
bias graph was generated to portray the risk of bias over-
all across the included trials.
Summary measures
Odds ratios with 95% confidence intervals were calcu-
lated and presented in the form of Forest plots we gen-
erated a league table, which ranks summary estimates in
order of the impact of the intervention on the primary
outcome measure [10]. In the league table, interventions
were ranked from those with the highest effect to the
lowest. A stacked bar chart rankogram was also created
to represent ranking probabilities and their uncertainty.
Analysis methods
Data with respect to events and number of patients in
individual trials were prepared and entered using Net-
MetaXL [16], to facilitate completion of a Bayesian net-
work meta-analysis using WinBUGS version 1.4.3 from
within Microsoft excel. We used the Markov Chain
Monte Carlo method of parameter estimation to obtain
posterior estimates of effects. Both vague prior and in-
formative prior results were presented in the Forest Plot.
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Zero cells were adjusted using an adjusted continuity
correction factor accounting for potential differences in
sample size, centered around 0.5.
As NetMetaXL is a relatively new tool, we run a separ-
ate set of analyses for the same data on GeMTC R pack-
age to validate our results with no noticeable differences.
We performed analysis with both fixed effects models
and random effects random-effect hierarchical models.
For Bayesian computation; detailed statistical approach
and diagnostics are provided in Additional file 1.
Assessment of consistency, model fit, and convergence
In NetMetaXL, ‘inconsistency plot’ was generated to fa-
cilitate visual assessment of conflicts between direct and
indirect evidence with limitation in our analysis due to a
substantial number of nodes on excel. Heterogeneity for
vague and informative priors was provided within the
forest plot results & Monte Carlo error < 5% of the
standard deviation (SD) used to assess convergence.
For GeMTC R package Gelman-Rubin statistics used
numerically and graphically to evaluate convergence while
deviance information criterion (DIC) was used for deter-
mining model fits and the model with smaller DIC value
was considered better.
Additional analyses
In addition to the main analysis we performed three other
analysis, the first excluding RCTs with any partial use of
hyperosmolar contrast media and in the other two RCTs
were divided according to baseline renal profile.
For each of the four analyses we performed sub-analysis
excluding studies with zero values as corresponding ef-
fects estimates may be subject to numerical instability,
generally over-estimate the effect, and that can be ob-
served in the wide associated confidence intervals.
Results
Study selection
A total of 32,596 study titles were identified in the initial
literature search, of which 200 fulfilled criteria for inclu-
sion [4, 5, 7, 17–209] (Fig. 1). Some studies were excluded
as some data were partially included or re-analyzed in a
Fig. 1 Flow Diagram
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follow-up study involved in our review [210–215]. A total
of 32,399 studies were excluded after remove duplication
the most common reasons for exclusions after full exam-
ination included observational methodology; different out-
come measures, inadequate definition of CI-AKI; unclear
evidence of randomization; old studies that did not com-
ply with eligibility criteria for more than one reason [216–
279]. The twelve studies published in a non-English lan-
guage included those from centers in Germany [280, 281],
China [282–287], Spain [288], France [289], Turkey [290]
and Italy [291]. Eight further potentially suitable studies
were identified in abstract form only, but were excluded
as no full-text article could be identified [292–299].
Study characteristics
Additional file 2 outlines individual study characteristics
(study inclusion and exclusion criteria; procedure per-
formed; baseline renal function; definition of CI-AKI
used in the study; contrast medium volume and osmolal-
ity). In total, 197studies fulfilled the inclusion criteria,
including three which had multiple trial arms requiring
separate analyses (Yang 2014, Kumar 2014 & Chen
2008). A total of 200 comparative analyses were there-
fore included in our analyses. Coronary angiography
accounted for 145 (72.5%) of the contrast-dependent
procedures were. Less frequently reported procedures
included contrast-enhanced CT imaging (n = 16, 8%),
peripheral angiography with/without angioplasty and
stenting (n = 3, 1.5%) endovascular aneurysm repairs
(EVAR) (n = 1, 0.5. %). Multiple procedures were in-
cluded in 35 studies (17.5%). Low osmolar contrast
agents were used in 111 (55.5%), iso-osmolar agents in
44 studies (22%), and hi-osmolar media in 3 studies
(1.5%). Twenty-six (13%) trials permitted physician dis-
cretion in the selection of contrast media, while a fur-
ther 16 (8%) did not specify the contrast medium
utilized. More recent studies we observed better design
with an exclusion for patients using alternative CI-AKI
prevention interventions from participation or stratified
those methods among arms of the trial.
Network structure
The relationship and comparisons between included
studies are demonstrated in the network diagram (Fig. 2).
Forty-four interventions are included in this network
(Table 1).
Network geometry
Data from 42,273 patients recruited to 200 trials investi-
gating 44 interventions were included in our analyses; a
summary of network characteristics is provided in
(Table 2). Nine hundred and forty-six pair-wise compari-
sons were possible, of which 81 used data from direct
comparisons in Additional file 3. The most commonly
investigated comparisons are between N-acetylcysteine
(NAC) and placebo (36 studies, 8,202patients); and
intravenous normal saline and intravenous sodium bicar-
bonate (24 studies, 5,481patients). The interventions
most commonly investigated were NAC, NaHCO3, Sta-
tins, Intravenous Hydration (I.V), and placebo or con-
trol. The characteristics of individual interventions are
outlined in Additional file 3.
Risk of bias
Risk of bias assessed by two authors (Khalid, Walsh). In
case of disagreement, other authors were consulted. Sum-
mary for individual studies provided in Additional file 4
while (Fig. 3) shows the risk of bias graph across all stud-
ies. Most of the studies demonstrated unclear to low risk
of bias while most of the high risk of bias were observed
in attrition bias domain. As the outcome measure (CA-
AKI) is dependent on laboratory results it seems reason-
able to assume the risk of bias attributed to blinding of
outcome assessment domain was low by default.
Synthesis of results
The Renal Association, British Cardiovascular Interven-
tion Society and the Royal College of Radiologists among
many other medical bodies recommend using intravenous
volume expansion as a prevention method for CA-AKI
[300]. Thus, we considered intravenous hydration clinic-
ally the reference intervention in this analysis, in addition
to the node size and the multiple arms within the network
which make it very good comparator.
A forest plot was generated to demonstrate odds ratio
generated from direct and indirect pair-wise compari-
sons. Effect estimates, and confidence intervals were in-
cluded for both vague and informative priors using a
random effects model. The overall heterogeneity for the
vague prior was 0.54 (95% CI 0.41–0.69), while that for
informative prior was 0.498 (95% CI 0.366–0.6403). The
SUCRA (surface under the cumulative ranking curve)
was utilized to generate a stacked bar chart rankogram
(Fig. 4). A league table arranging summary of effect
estimate, and ranking interventions according to impact
on the outcome can be found in Additional file 3 in
addition to the Forest Plot, characteristics of interven-
tions and comparisons and analysis specifications. The
probabilities of being ranked for the best each interven-
tion is summarized in (Table 3) while the numerical
values follow the Rankogram results the list of interven-
tions in the first column follow the league table hier-
archy and a good example is Allopurinol which included
in 4 studies ranked best in both Rankogram (0.9647) and
League Table while Silymarin was 3rd (0.7934) and last
respectively and was included in one study.
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Sensitivity analysis
Flow chart for the main analyses and sub-analyses is
included in Additional file 1. From the main analysis
200 RCTs we run sub-analysis that includes 184
RCTS in which we exclude all studies with zero
values (n = 7). All figures and tables are included in
Additional file 3.
The second analysis involved 173 RCTs after excluding
studies reporting any use of hyperosmolar contrast
media, the sub-analysis without zero values RCTs in-
clude 159 RCTS.
Trials with high baseline renal profile were in analysis 3
which includes 112 RCTs and sub-analysis for 105 RCTS.
The 4th analysis includes 60 and 53 RCTs respectively.
Analysis specifications, figures and tables provided in
Additional file 5, Additional file 6 and Additional file 7.
When interpreting sub-analyses results in conventional
direct pairwise comparisons the main effect results from
the size of the excluded studies because there is no ex-
clusion for interventions and they will always be present
at both sides of the forest plot. This impact the overall
diamond shape effect estimates size and confidence
Fig. 2 Network Diagram: The size of each intervention node is proportional to the number of patients included in the trials, while the thickness
of interconnecting lines is proportional to the number of pairwise comparisons between any two interventions
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interval will either shift towards one treatment or touch-
ing the line of no effect indicating no superiority for any
intervention. This is different in Network Meta-analysis
in which we can see changes in connections dynamic
(Network Diagram) and interventions numbers repre-
sented by node sizes and number of connections be-
tween them both can be affected or totally removed by
the excluding studies. In the latter case the Network
Diagram and characteristics of interventions and com-
parisons provide detailed visualization to help compare
the main vs sub-analysis. In Additional file 3, Additional
file 5, Additional file 6 and Additional file 7 we detailed
all excluded studies, the affected interventions, Network
Diagrams and the characteristics of the interventions
and comparisons.
Assessment of consistency
An ‘inconsistency plot’ (Fig. 5) was generated to assess
inconsistency. Inconsistency in network meta-analysis is
similar to heterogeneity in conventional meta-analysis but
consistency concerns the relation between the treatments
whereas heterogeneity concerns the variation between
trials within a pairwise comparison between two treat-
ments. Inconsistency is caused by imbalances in the distri-
bution of effect modifiers in the direct and indirect
evidence. Effects modifiers in this large sample include
but are not limited to patient factors, drug interactions,
contrast media volume and type and renal function pre-
intervention. Inevitably, some modifiers exist that cannot
be completely eliminated in large multi-treatment network
meta-analysis, leading to some inconsistency, indicating a
need for careful interpretation of the results [301]. The
consistency plot shows individual data points’ posterior
mean deviance contributions for the consistency model
(horizontal axis) and the unrelated mean effects model
(vertical axis) along with the line of equality. In our analysis,
the main limitation is excel inability to handle a large
amount of nodes. However, there should be a consideration
Table 1 Interventions within Network Diagram
NO Drug Abbreviation Patients
1 I.V Hydration I.V 5136
2 Statins Sta 3040
3 Furosemide Fur 554
4 NAC NAC 6095
5 Trimetazidine Tri 352
6 NaHCO3 NaH 3393
7 PGE1 PGE 304
8 MgSO4 MgS 62
9 Pentoxifylline Pen 438
10 Placebo Pla 7044
11 Control Con 9120
12 Allopurinol All 204
13 BNP BNP 744
14 Probucol Pro 198
15 α-tocopherol α-t 312
16 γ-tocopherol γ-t 102
17 Oxygen Oxy 346
18 Amlodipine and Valsartan Aml 45
19 K/Na citrate K/N 203
20 Nicorandil Nic 291
21 Ascorbic Acid Asc 552
22 Alpha-Lipoic Acid Alp 139
23 Oral Hydration Ora 254
24 Nebivolol Neb 40
25 Anisodamine Ani 192
26 RIPC RIP 608
27 Theophylline The 384
28 Hypothermia Hyp 58
29 Glutathione Glu 421
30 MESNA MES 51
31 ACEI AC 129
32 Aminophylline Ami 45
33 Iloprost Ilo 118
34 Acetazolamide Ace 94
35 ANP ANP 202
36 Zinc Zin 18
37 Dialysis Dia 293
38 Fenoldopam Fe 333
39 ERAs ER 77
40 CCB CC 42
41 Dopamine Do 48
42 Mannitol Ma 35
43 Cordyceps Co 88
44 Silymarin Si 69
ACEI Angiotensin Converting-Enzyme Inhibitor, ANP Atrial Natriuretic Peptide,
BNP B-Type Natriuretic Peptide, CCB Calcium Channels Blockers, CI-AKI Contrast
Induced Acute Kidney Injury, CIN Contrast Induced Nephropathy, ERAs
Endothelin Receptor Antagonism, MESNA 2-Mercaptoethane Sulfonate Sodium,
MgSo4 Magnesium Sulphate, NAC N-acetyl cysteine, NaHco3 Sodium
Bicarbonate, PGE1 Prostaglandin E1, RIPC Remote Ischemic Preconditioning
Table 2 Network Characteristics
Characteristic Number
Number of Interventions 44
Number of Studies 200
Total Number of Patients in Network 42,273
Total Number of Events in Network 4602
Total Possible Pairwise Comparisons 946
Total Number Pairwise Comparisons with Direct Data 81
Number of Two-arm Studies 179
Number of Multi-Arms Studies 21
Number of Studies with No Zero Events 184
Number of Studies With At Least One Zero Event 16
Number of Studies with All Zero Events 2
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Fig. 3 Risk of Bias Graph
Fig. 4 Rankogram: ranking the interventions for the probability of being the best, the interventions are colour coded; the first column represents
the chance of being first best and 2nd column is the chance of being 2nd best and so on. i.e. the first column represent the chance of being first
best cmparing all interventions out of100% and the second represent the chance of being second best out of 100% up to last column in this
case number 44 (nuber of interventions); the overall ranking for each treatment is the sum of scores through out the 44 compasrisons. The
overall numerical value is presented in Table 3
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of individual pairwise comparisons effect estimates gener-
ated within the forest plot.
In GeMTC R analyses I2 statistics and DIC was much
smaller for Random effect indicating less heterogeneity
compared with a fixed effect which is expected to pro-
vide the nature of the network. Detailed scores are pre-
sented in Additional file 1 while Gelman and Rubin’s
convergence diagnostics were added to corresponded
analyses in Additional file 3, Additional file 5, Additional
file 6 and Additional file 7.
In general, the main analysis reviled some interesting re-
sults with Allopurinol, Prostaglandin E1 (PGE1) & Oxygen
were ranked high with good both statistical and clinical
outcomes in relatively fewer number of studies comparing
with other interventions studied in larger number of RCTs
e.g. NAC, Statins, Hydration, NaHco3 and RIPC. The re-
sults were stable throughout different sub analysis consid-
ering the changes in network diagram being affected by
excluded studies in all 7 networks. The model fitting and
the consistency within the network was good considering
the large size and it is understandable that it was better fit-
ted in the 7 sub-groups analysis specially after excluding
zero values studies. It is very important here to remember
in network ranking is the probability of being the best
within the interventions and we need to look at the forest
plot for each comparison.
Discussion
Summary of evidence
This is a systematic review and network meta-analysis
(multi-treatment comparison) of studies investigating
methods for the prevention of contrast-induced nephrop-
athy. We identified 200 eligible trials, of which 3 had 2
different arms and thus analysed separately. Data from a
total of 42,273 patients undergoing 44 different interven-
tions were included. Intravenous hydration (Nacl) was
used as the reference treatment as there is a consensus
supported by evidence accepting it as a method of preven-
tion with no clear superiority for other I.V fluids [81]. in
our network it was also included in many multiple arms
Table 3 Interventions ranking the treatments names column
follow the league table (which arranges the presentation of
summary estimates by ranking the treatments in order of most
pronounced impact on the outcome under consideration) the
numerical values represents the cumulative results of the
probability of being best in which the highest score is 1 or
100% (see Rankogram)
Treatment SUCRA Treatment SUCRA
Allopurinol 0.9647 NaHCO3 0.3419
MESNA 0.9427 Pentoxifylline 0.3391
PGE1 0.7809 I.V Hydration 0.3124
α-tocopherol 0.7614 Placebo 0.2694
Oxygen 0.7527 Oral Hydration 0.2517
K/Na citrate 0.7469 Hypothermia 0.2021
Trimetazidine 0.7151 Control 0.1658
Probucol 0.7042 Amlodipine and Valsartan 0.05485
γ-tocopherol 0.689 ACEI 0.5783
BNP 0.6767 Aminophylline 0.6593
Anisodamine 0.6594 Iloprost 0.7481
Nicorandil 0.6442 Acetazolamide 0.6242
Theophylline 0.629 ANP 0.3291
RIPC 0.5692 Zinc 0.198
Statins 0.5497 Dialysis 0.4319
MgSO4 0.5177 Fenoldopam 0.2296
NAC 0.4592 ERAs 0.06734
Nebivolol 0.4543 CCB 0.7249
Ascorbic Acid 0.4433 Dopamine 0.1916
Alpha-Lipoic Acid 0.4322 Mannitol 0.1905
Furosemide 0.4027 Cordyceps 0.4459
Glutathione 0.3554 Silymarin 0.7934
Analysis Random Effects (Vague)
Fig. 5 Inconsistency Plot: Inconsistency is similar to heterogeneity in conventional meta-analysis, but consistency concerns the relation between
the direct and indirect evidence. The consistency plot shows individual data points’ posterior mean deviance contributions for the consistency
model (horizontal axis) and the unrelated mean effects model (vertical axis) along with the line of equality
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RCTs which make it statistically a very good comparator.
While only randomized control trials were included, de-
fining the outcome and inclusion criteria, help to
minimize the number of effect modifiers at play in differ-
ent studies, thus minimising inconsistency. However, the
assumption of homogeneity should be accepted with cau-
tion in light of the large numbers of trials and patients
included.
It is very important for readers more familiar with
general probability measure in which the value one is
assigned to the entire probability space to recognize
that SUCRA use posterior probabilities for each treat-
ment to be among the n - best options (cumulative
probabilities) thus the sum add to > 1. The word best
referred to the number of times that an intervention
ranks first out of the total number of random sam-
ples [14] In Rankogram the first column represent
the chance of being first best out of100% and the sec-
ond represent the chance of being second best up to
last column; the overall ranking for each treatment is
the sum and that the reason each treatment probabil-
ity is calculated out of 100%.
We can generally categorize the 44 ranked interven-
tions in groups. The first group is high ranked interven-
tions with relatively fewer number of studies and this
group is mainly for further research consideration des-
pite good design RCTs, good clinical outcomes, and our
conscious effort to eliminate the effect of small node ef-
fect on the network and the fact we accommodate and
accounted for the different in interventions size when
calculating the probability but we cannot ignore that this
may still play in favour of small studies and we think
they deserve another look with larger well-designed tri-
als, this group includes mainly Allopurinol, Prostaglan-
din E1 (PGE1) & Oxygen; Allopurinol a xanthine
oxidase Inhibitor used for treatment of gout and man-
agement of hyperuricemia associated with chemotherapy
and was assessed in 4 trials with 204 patients with recent
published evidence suggesting some benefits [302] while
PGE1 in 4 trails with total 304 patients. Interestingly
Oxygen was highly ranked before and after exclusion of
zero events studies and the total number of patients was
346 in 2 studies.
The scorned group is the middle group which included
in decent number of studies and the interventions in this
group with safe and or well tested profile can be used in
patient care at the same time continuously evaluated
and this group can include RIPC, Statins (which usually
in use specially by cardiac and vascular patients), NAC,
NaHco3, I.V hydration, Oral hydration and hypothermia.
This group needed the physician to consult his local
guidelines after evaluating each patient individually and
some interventions like hypothermia is not applicable
for all patients.
The sub-analyses in our network for was performed
after excluding studies with zero events to eliminate favor-
able effect profile. It produced better statistical results and
helped compare the results without the interventions in-
volved in a small number of trials.
Research & Clinical impact
For health care providers, the results of this meta-analysis
do not suggest changes to current clinical practice. The
prevention methods assessed in large studies should be
evaluated on a case-by-case basis, bearing in mind the co-
morbidities, clinical needs and prior risk factors of the in-
dividual patient with special consideration to national and
local guidelines. Interventions with safe profile and sup-
portive evidence from direct pair-wise meta-analysis can
be considered as additional or second-line therapies for
CA-AKI prevention. For clinical researchers, the highly-
ranked treatments with relatively small number of trials
merit further examonation in larger RCTs.
Limitations
One limitation of this meta-analysis is the exclusion of
non-English language studies (n = 12). The inclusion of
these studies may add to the supportive evidence for the
use of some interventions, although the effect size of
these trials is likely to be minimal in light of the sample
sizes in question. Another limitation is the difference in
contrast media used which may affect the outcomes; we
excluded studies that used hyperosmolar contrast media
to minimise this effect with some evidence suggesting
similar CIN incidence for iso and low-osmolar CM in
coronary angiography patients [303]. In large Network,
another consideration is our inability to account for
other possible effect modifiers, and our assumptions re-
garding homogeneity and similarity across a large num-
ber of studies thus it is important to look at each
intervention ranking through the multiple analyses pro-
vided in the supplemnts.
While preparing this network meta-analysis a pairwise
meta-analysis was published .comparing N-acetylcysteine,
sodium bicarbonate, statins and ascorbic acid for CA-AKI
reduction [304]. The data was obtained from controlled
trials that used intravenous (IV) or intra-arterial contrast.
The results of statins plus I.V saline vs I.V saline show
clinically but not statistically significant difference. When
comparing Sodium bicarbonate to I.V saline it was clinic-
ally better, but again the difference was not statistically sig-
nificant. However Ascorbic acid was better both clinically
and statistically vs I.V saline and show no such difference
when compared with NAC. A similar result can be ob-
served in our ranking table with 0.5497, 0.4433, 0.3419
and 0.3124 probability of being rank for statins, ascorbic
acid, Sodium bicarbonate and I.V saline consequently. Al-
though direct comparisons results were provided within
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forest plot in our network, we think the results from pair-
wise reviews is important; the nature of conventional
meta-analysis prevent utilization of multiple arms trials
and creating indirect comparison but it can be used to
look at sections of more comprehensive network-meta-
analysis in addition to the fact that It is more flexible in
terms of subgroup analysis and thus assessment of effects
modifiers e.g. type of contrast media in this case.
Conclusion
This systematic review and network meta-analysis pro-
vide a comprehensive analysis of currently utilized CA-
AKI prevention interventions. Results arising from this
network identified some highly-ranked interventions
throughout analyses and sub-analyses (e.g., Allopurinol,
PGE1 & Oxygen) which were included in small number
of trials and merit further examination on a larger scale
in the context of a well-designed RCTs.
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